Showing all 2 results
Lisinopril Tablet
FreeProduct Composition & Available Portfolio Range
We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation. Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization. Nifedipine Tablet
FreeProduct Composition & Structural Formats
We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.
Active Ingredient Available Strengths Formulation Mechanism Primary Clinical Target Nifedipine IP / BP / USP 10 mg Immediate or Modified Release Acute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor. Nifedipine IP / BP / USP 20 mg Sustained / Retard Matrix Daily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina.
